Trial Profile
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacogenomic; Therapeutic Use
- 08 Sep 2015 Status changed from recruiting to completed as per data presented in the European Neuropsychopharmacology.
- 08 Sep 2015 Results published in the European Neuropsychopharmacology.
- 09 Jul 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.